Posaconazole

Drugs of Today

Volumn 41, Issue 6, 2005, Pages 393-400

  Ashley, Elizabeth S Dodds ^a,b   Alexander, Barbara D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Campbell University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; MIDAZOLAM; MYLANTA; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RIFABUTIN; RITONAVIR; TRIAZOLE DERIVATIVE; VORICONAZOLE; ZIDOVUDINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CHROMOMYCOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEUTROPENIA; PHOTOSENSITIVITY DISORDER; REVIEW; VISUAL DISORDER; VOMITING; ZYGOMYCETES;

ANTIBIOTICS, ANTIFUNGAL; CLINICAL TRIALS; FUNGI; HUMANS; MYCOSES; TRIAZOLES;

EID: 23044463748     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.6.898145     Document Type: Review

References (35)

1. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39: 309-17.
2. Pappas, P.G., Morgan, J., Hajjeh, R.A., et al. Prospective surveillance for invasive fungal infections (IFIs) in hematopoetic stem cell (HSCTs) and solid organ transplant recipients (SOTs) in the United States. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (September 14-17, Chicago, IL) 2003, Abstr. M-1010.
3. Marr, K.A., Carter, R.A., Crippa, F., Wald, A., Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34: 909-17.
4. Marr, K.A., Carter, R.A., Boeckh, M., Martin, P., Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002, 100: 4358-66.
5. Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., Courtney, R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004, 48: 3543-51.
6. Pfaller, M.A., Messer, S.A., Boyken, L. et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004, 48: 201-5.
7. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001, 45: 2862-4.
8. Ostrosky-Zeichner, L., Rex, J.H., Pappas, P.G. et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47: 3149-54.
9. Sanglaard, D., Kuchler, K., Ischer, F., Pagani, J.-L., Monod, M., Bille, J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates form AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995, 39: 2378-86.
10. Sabatelli, J., Leobenberg, D., Mendrick, A. et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole and amphotericin B against approximately 18,000 strains of clinically significant yeasts and moulds. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (October 30-November 2, Washington, DC) 2004, Abstr. M-1810.
11. Manavathu, E.K., Cutright, J.L., Loebenberg, D., Chandrasekar, P.H. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000, 46: 229-34.
12. Sun, Q.N., Fothergill, A.W., McCarthy, D.I., Rinaldi, M.G., Graybill, J.R. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002, 46: 1581-2.
13. Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J., Laughlin, M. Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005, 44: 211-20.
14. Courtney, R., Wexler, D., Radwanski, E., Lim, J., Laughlin, M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004, 57: 218-22.
15. Courtney, R., Sansone, A., Calzetta, A., Martinho, M., Laughlin, M. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (September 14-17, Chicago, IL) 2003, Abstr. A-1604.
16. Courtney, R., Radwanski, E., Lim, J., Laughlin, M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004, 48: 804-8.
17. Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003, 47: 2788-95.
18. Courtney, R., Wexler, D., Statkevich, P., Lim, J., Batra, V., Laughlin, M. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (September 27-30, San Diego, CA) 2002, Abstr. A-1838.
19. Courtney, R., Sansone, A., Smith, W. et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005, 45: 185-92.
20. Courtney, R., Laughlin, M., Gontz, H. et al. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease. Annual Meeting of the American Association of Pharmaceutical Scientists (October 29-November 2, Indianapolis, IN) 2000, Abstr. 3495.
21. Raad, I., Chapman, S., Bradsher, R. et al. Posaconazole (POS) Salvage Therapy for Invasive Fungal Infections (IFI). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (October 30-November 2, Washington, DC) 2004, Abstr. M-669.
22. Skiest, D., Vazquez, J., Graybill, J. et al. Open-label trial of posaconazole for azole-refractory oropharyngeal and esophageal candidiasis in HIV/AIDS subjects: Final analysis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (October 30-November 2, Washington, DC) 2004, Abstr. M-1027.
23. Catanzaro, A., Cloud, G., Stevens, D. et al. Safety and tolerance of posaconazole (SCH 56592) in patients with nonmeningeal disseminated coccidioidomycosis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (September 17-20, Toronto, Ontario, Canada) 2000, Abstr. 1417.
24. Greenberg, R., Herbrecht, R., Langston, A. et al. Posaconazole therapy for refractory invasive zygomycosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (September 14-17, Chicago, IL) 2003, Abstr. M-1757.
25. Stevens, D.A., Rendon, A., Gaona, V. et al. Posaconazole (POS) therapy for refractory coccidioidomycosis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), (October 30-November 2, Washington, D.C.) 2004, Abstr. M-663.
26. Sansone, A., Courtney, R., Brundage, T., Laughlin, M. Safety and tolerability of posaconazole: Evaluation of 18 controlled, healthy volunteer studies. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (October 30-November 2, Washington, DC) 2004, Abstr. M-1099.
27. Sansone, A., Courtney, R., Mellars, L. et al. Posaconazole has no clinically significant effect on QTc interval in healthy volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (October 30-November 2, Washington, DC) 2004, Abstr. A-1100.
28. Graybill, J.R., Raad, I., Negroni, R., Corcoran, E., Pedicone, L. Posaconazole (POS) long-term safety in subjects with invasive fungal infections (IFIs). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (October 30-November 2, Washington, DC) 2004, Abstr. M-1025.
29. Wexler, D., Courtney, R., Richards, W., Banfield, C., Lim, J., Laughlin, M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004, 21: 645-53.
30. Courtney, R., PPS, Laughlin, M., Lim, J., Clement, R., Batra, V. Effect of posaconazole on the pharmacokinetics of cyclosporine. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (December 16-19, Chicago, IL) 2001, Abstr. 27.
31. Sansone, A., Belle, D., Statkevich, P. et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy adults. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (September 14-17, Chicago IL) 2003, Abstr. A-1603.
32. Ngo, L., Keung, A., Aweeka, F. et al. A pharmacokinetic drug interaction study of posaconazole with zidovudine/lamivudine and protease inhibitors in HIV-infected patients. Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS) (October 29-November 2, Indianapolis, IN) 2000, Abstr. 3455.
33. Ghosal, A., Hapangama, N., Yuan, Y. et al. Identification of human UDP-glucuronosyl-transferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004, 32: 267-71.
34. Courtney, R., Statkevich, P., Laughlin, M. et al. Potential for a drug interaction between posaconazole and rifabutin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (December 16-19, Chicago, IL) 2001, Abstr. 29.
35. Courtney, R., Statkevich, P., Laughlin, M. et al. Potential for a drug interaction between posaconazole andphenytoin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (December 16-19, Chicago IL) 2001, Abstr. 28.